Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
31 Janeiro 2025 - 9:12AM
Edgar (US Regulatory)
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Basel, January 31, 2025
|
|
Re:
|
Notice of disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934
|
Ladies and Gentlemen:
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby
provided that Novartis AG has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission on January 31, 2025.
Respectfully submitted,
Novartis AG
|
|
/s/ Karen L. Hale
|
|
/s/ Harry Kirsch
|
|
|
Karen L. Hale
Chief Legal Officer of Novartis
|
|
Harry Kirsch
Chief Financial Officer of Novartis
|
|
Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Novartis Ag Basel Namen ... (PK) (USOTC:NVSEF)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
Notícias em tempo-real sobre Novartis Ag Basel Namen Akt (PK) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Novartis Ag Basel Namen Akt (PK)
